March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Long Term Pilot Study Of Oct-guided Monthly Ranibizumab For Uveitic Cystoid Macular Edema
Author Affiliations & Notes
  • Thomas A. Albini
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • Janet L. Davis
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • Footnotes
    Commercial Relationships  Thomas A. Albini, Genentech, Inc. (F); Janet L. Davis, None
  • Footnotes
    Support  Genentech, Inc
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 1184. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Thomas A. Albini, Janet L. Davis; Long Term Pilot Study Of Oct-guided Monthly Ranibizumab For Uveitic Cystoid Macular Edema. Invest. Ophthalmol. Vis. Sci. 2012;53(14):1184.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : This prospective pilot study documents the effects of monthly optical coherence tomography (OCT)-guided ranibizumab over one year in patients with uveitic cystoid macular edema (UCME) and otherwise quiet noninfectious uveitis.

Methods: : Five eyes in 5 patients with controlled noninfectious uveitis and UCME were enrolled in a prospective pilot study of monthly ranibizumab (0.5mg) intravitreal injections. Injections were repeated monthly over 12 months if there was an increase in or persistence of retinal thickening or cysts. In addition to each monthly visit, patients were examined one week following each injection.

Results: : All 5 patients finished 12 months of follow-up. Mean early treatment diabetic retinopathy study letters gained was 12 letters (p=0.02) between the entry and final visits. At 12 months mean reduction in central retinal thickness was 45% (p=0.006). The mean number of injections given was 6.4 injections over 12 months. The mean number of injections was 4.6 injections in the first 6 months of the study and 1.8 in the second six months (p=0.0086). Adverse events included subconjunctival hemorrhage, post-injection discomfort, and in one patient, recurrence of anterior uveitis two weeks following injection, with progression of cataract and glaucoma.

Conclusions: : OCT-guided monthly ranibizumab led to improved visual acuity and decreased retinal thickness. Frequent injections were required and were well tolerated. The number of injections required was significantly less in the second six month period than in the first.

Clinical Trial: : NCT00826618

Keywords: uveitis-clinical/animal model • macula/fovea • drug toxicity/drug effects 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.